Pseudopodium-enriched atypical kinase 1 regulates the cytoskeleton and cancer progression [corrected].
about
Microparticle conferred microRNA profiles--implications in the transfer and dominance of cancer traitsTrespassing cancer cells: 'fingerprinting' invasive protrusions reveals metastatic culpritsFatty acid synthase is a key target in multiple essential tumor functions of prostate cancer: uptake of radiolabeled acetate as a predictor of the targeted therapy outcomeSwitching Roles of TGF-β in Cancer Development: Implications for Therapeutic Target and Biomarker StudiesTemporal regulation of EGF signalling networks by the scaffold protein Shc1Dynamin 2 potentiates invasive migration of pancreatic tumor cells through stabilization of the Rac1 GEF Vav1A robust methodology to subclassify pseudokinases based on their nucleotide-binding properties.A signaling network stimulated by β2 integrin promotes the polarization of lytic granules in cytotoxic cellsA hypusine-eIF5A-PEAK1 switch regulates the pathogenesis of pancreatic cancerPEAK1, a novel kinase target in the fight against cancer.PEAK1 Acts as a Molecular Switch to Regulate Context-Dependent TGFβ Responses in Breast Cancer.The pseudokinase SgK223 promotes invasion of pancreatic ductal epithelial cells through JAK1/Stat3 signaling.A novel method for RNA extraction from FFPE samples reveals significant differences in biomarker expression between orthotopic and subcutaneous pancreatic cancer patient-derived xenografts.Eukaryotic Translation Initiation Factor 5A (EIF5A) Regulates Pancreatic Cancer Metastasis by Modulating RhoA and Rho-associated Kinase (ROCK) Protein Expression LevelsAnalysis of SRC oncogenic signaling in colorectal cancer by stable isotope labeling with heavy amino acids in mouse xenograftsDynamic phosphorylation of tyrosine 665 in pseudopodium-enriched atypical kinase 1 (PEAK1) is essential for the regulation of cell migration and focal adhesion turnoverTemporal Phosphoproteome Dynamics Induced by an ATP Synthase Inhibitor Citreoviridin.Phosphotyrosine profiling of curcumin-induced signaling.Procedures for the biochemical enrichment and proteomic analysis of the cytoskeletome.Mouse Fyn induces pseudopodium formation in Chinese hamster ovary cells.Oncogenic signaling by tyrosine kinases of the SRC family in advanced colorectal cancer.Techniques to examine nucleotide binding by pseudokinases.MS/MS-based strategies for proteomic profiling of invasive cell structures.ITGA1 is a pre-malignant biomarker that promotes therapy resistance and metastatic potential in pancreatic cancer.eIF5A-PEAK1 Signaling Regulates YAP1/TAZ Protein Expression and Pancreatic Cancer Cell Growth.Cellular and molecular aspects of pancreatic cancer.Homo- and Heterotypic Association Regulates Signaling by the SgK269/PEAK1 and SgK223 PseudokinasesQuantitative profiling of spreading-coupled protein tyrosine phosphorylation in migratory cells.KRas induces a Src/PEAK1/ErbB2 kinase amplification loop that drives metastatic growth and therapy resistance in pancreatic cancer.Proximity biotinylation provides insight into the molecular composition of focal adhesions at the nanometer scale.C-terminal Src kinase-mediated EPIYA phosphorylation of Pragmin creates a feed-forward C-terminal Src kinase activation loop that promotes cell motility.Structure of SgK223 pseudokinase reveals novel mechanisms of homotypic and heterotypic association.Proteomic and biochemical methods to study the cytoskeletome.The crystal structure of pseudokinase PEAK1 (Sugen Kinase 269) reveals an unusual catalytic cleft and a novel mode of kinase fold dimerization.The pseudokinases SgK269 and SgK223: A novel oncogenic alliance in human cancer.Ascending the PEAK1 toward targeting TGFβ during cancer progression: Recent advances and future perspectives.PEAK1, acting as a tumor promoter in colorectal cancer, is regulated by the EGFR/KRas signaling axis and miR-181d.Inhibition of DDR1-BCR signalling by nilotinib as a new therapeutic strategy for metastatic colorectal cancer.Pseudopodium-enriched atypical kinase 1 mediates angiogenesis by modulating GATA2-dependent VEGFR2 transcription.
P2860
002e37b61724d061acb44842d48ca1ae4ff129b110f60d009fb4017c6231daaa6dc50e686329cc7b202490e1e4a51ca8ef692a799b7b332811e92dcb61ebb6e42257bed77481944c0d494b42564eb3627374863bd60d0cee8e14759986cbe0532216ef8473f6aa14b98c9772d9ad1fceab6e664471c629d680036ce282dd3d8872854a6d94c1ea7aa65c30ee93b94df54c1a72ae19458267187ea997d97f8f81a58f0313a6d473e22fddfe24ff254c061aa1cee3b93b8b8cb8e7a0344229a34bc2e20ce3688cfbb8
P248
Q21245759-CA8EA1BE-252C-410A-AE64-BFC39C06F9A3Q26997307-B2A957BB-FAC8-492C-AE19-188BD754378DQ27318509-A5296AEB-F522-403B-A3B2-639DED6799A1Q28079488-EDF81771-6F01-44FF-8188-A0FD3E743A39Q28294401-8A4B06E0-9411-42A7-B3CA-6BE66EC51A80Q30009890-01938EF9-8269-4787-8DB8-06AC37C3E259Q34376382-0F860A8E-437F-43F2-BB9F-FCFC8F69CB9FQ34383550-CE31FD9B-A888-4FF3-9D47-962186D4BB76Q34518559-DB0BFA01-6E47-4858-8FE4-EA29902662D9Q34675121-37A50015-C567-49C7-86F3-632B1BC70773Q35744180-E35989FD-6A58-479D-B985-3532FD987C94Q35896807-624912F8-6703-4577-BEDE-C6E63E697A68Q36125108-1F1F2FD4-11BA-4002-A6C0-AE965CC51B35Q36444280-213B0009-286D-4C7A-8396-5EB1187DB4DAQ36455713-BFD3D513-DCEA-4105-BF8A-0B26C85F4AB6Q36508540-8D3DBD9A-6BB7-43C9-803E-B2E70853715CQ36604376-BF1D6200-871A-47D0-A3F3-DE4897FE64D9Q37006455-7EEFD4F6-BB61-40D1-9676-E3EFCCE3918CQ37625933-D9726DE4-AA4E-41D4-AD34-EDC567840223Q37681074-C8098C26-B357-4BB9-8C84-1954BC9EE84DQ38031834-84A1B548-B2C2-48C7-8938-FC066DD5F6A0Q38122229-10622BDA-5107-4175-9138-6E3BF1452CF9Q38258895-5D5FD57D-C5A3-406C-93E5-538C7A12A5F1Q38601572-21E7AF30-D9FD-46D7-85B7-639B60FE9482Q38708727-3D049C81-04DA-4E74-BDEF-E48E47FC3E84Q38730160-D5A15169-0D56-419C-B5DB-71D72BA9D2ADQ38751467-D9508B00-49F5-4375-979D-E11FA9F8E2EEQ38828489-8625C419-5B51-43E8-9C1C-A3EC7B2A7432Q39347740-18DF719F-37E4-44A4-9891-52B914167658Q39682618-A9209039-148A-4413-83AC-80EF3FC4850DQ42288794-E14CB59D-4E38-4E16-A0D5-C3876CA27633Q42611868-31A94F23-B539-43C7-9BA9-5FAE6C238E60Q42642200-2F8A0779-E362-4786-AB8E-462088FA9FFAQ47322504-B2735C32-05F1-4A09-B54F-28C346D1D15EQ47438670-0B6B95DB-8F07-4799-ADE8-8479E3AE60BEQ49385083-2B686F45-4AF7-48C1-A9BE-527C150993E8Q49959181-C30E6662-D473-4F20-B147-BBFF6D4BA19CQ50036937-F22E251A-505B-4653-893A-9D1BE464E74DQ54959791-B732419C-0F2B-4CD8-9F36-CD5BB028A490
P2860
Pseudopodium-enriched atypical kinase 1 regulates the cytoskeleton and cancer progression [corrected].
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
name
Pseudopodium-enriched atypical ...... cancer progression [corrected]
@nl
Pseudopodium-enriched atypical ...... ancer progression [corrected].
@ast
Pseudopodium-enriched atypical ...... ancer progression [corrected].
@en
Pseudopodium-enriched atypical ...... ancer progression [corrected].
@en-gb
type
label
Pseudopodium-enriched atypical ...... cancer progression [corrected]
@nl
Pseudopodium-enriched atypical ...... ancer progression [corrected].
@ast
Pseudopodium-enriched atypical ...... ancer progression [corrected].
@en
Pseudopodium-enriched atypical ...... ancer progression [corrected].
@en-gb
prefLabel
Pseudopodium-enriched atypical ...... cancer progression [corrected]
@nl
Pseudopodium-enriched atypical ...... ancer progression [corrected].
@ast
Pseudopodium-enriched atypical ...... ancer progression [corrected].
@en
Pseudopodium-enriched atypical ...... ancer progression [corrected].
@en-gb
P2093
P2860
P921
P3181
P356
P1476
Pseudopodium-enriched atypical ...... cancer progression [corrected]
@en
P2093
Greg T Cantin
Hop S Tran Cao
Jeanne M Bristow
John R Yates
Jonathan A Kelber
Michael Bouvet
Richard L Klemke
Robert M Hoffman
Sharmeela Kaushal
Thomas S Edgington
P2860
P304
10920-10925
P3181
P356
10.1073/PNAS.0914776107
P407
P50
P577
2010-06-01T00:00:00Z